Cambridge Cognition Holdings plc (COG) Ordinary 1p
- Add to watchlist
- Create an alert
- This stock can be held in a
Business summary
Cambridge Cognition Holdings plc is a United Kingdom-based company, which is engaged in developing and marketing digital solutions to assess brain health, principally in the United Kingdom, the United States and Europe. Its products include CANTAB, Electronic Clinical Outcomes Assessment (eCOA), NeuroVocalix, Winterlight, Cognition Kit, Clinpal, eConsent, and AQUA. CANTAB Connect gives the control to manage and deliver battery of touchscreen and voice assessments, as well as fully customizable electronic questionnaires and scales. The Company’s therapeutic areas include attention deficit hyperactivity disorder (ADHD), Alzheimer’s Disease, Autism Spectrum Disorder, Cognitive Safety, Core Cognitive Function, Depression, Down’s Syndrome, Drug Abuse Liability, Epilepsy, Huntington’s Disease, Multiple Sclerosis, Neuromuscular Disorders, Obsessive Compulsive Disorder, Parkinson’s Disease, Schizophrenia, Stroke and Cerebrovascular Disease, and Traumatic Brain Injury.
Contact details
Important dates
General stock information
- EPIC:
- COG
- ISIN:
- GB00B8DV9647
- Market cap:
- £14.23 million
- Shares in issue:
- 41.87 million
- Sector:
- Health Care Equipment & Services
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.